MedTrace Logo

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114

NCT05200273 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-01-20

No results posted yet for this study

Summary

A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK114.

Conditions

  • Advanced or Metastatic Solid Tumors
  • Malignancy
  • Metastasis

Interventions

DRUG

AK114

AK114 administered by subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • Alex HL Wong, MMedSc · Akeso

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2023-12-30
Completion
2023-12-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05200273 on ClinicalTrials.gov